Share this article on:

Editorial introductions

Section Editor(s): Klastersky, Jean; Sosa, Julie Ann; Hainaut, Pierre; Plymoth, Amelie

doi: 10.1097/CCO.0b013e32835cb881
Editorial introductions

Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue.

Back to Top | Article Outline


Jean Klastersky

Professor Klastersky is Head of the Department of Medicine at the Institut Jules Bordet in Brussels, Belgium and has been Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles, Belgique since 1977.

Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Medécine, Chirurgie et Accouchements). From 1967 to 1968 he was Chief-Resident at Boston City Hospital, USA and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory, Harvard Medical School, USA. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970 before taking up his current position in 1977.

Professor Klastersky was a founding member of the European Lung Cancer Working Party and has been its President since 1978. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000, and has been Visiting Professor of Medical Oncology at Charles University, Prague, Czech Republic, since 1994.

Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Disease Society of American, the International Association for the Study of Lung Cancer, and various other international and national medical and/or oncological societies. Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books. As well as serving as Editor of Current Opinion in Oncology, he is also Editor in Chief of Topics on Supportive Care in Cancer.

Back to Top | Article Outline


Julie Ann Sosa

Julie Ann Sosa, MA MD is Associate Professor of Surgery and Medine (Oncology) in the Sections of Surgical Oncology and Endocrine Surgery at the Yale University School of Medicine, USA. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. Her research interests are in health services and clinical trials. She is widely published in outcomes analysis, as well as cost-effectiveness analysis, meta-analysis, and survey-based research. At Yale, she is the principal investigator for several international trials using novel drug therapies for locally advanced and metastatic thyroid cancer. She is on the editorial boards of the Journal of Clinical Endocrinology and Metabolism, the Journal of Thyroid Research, and the Journal of Surgical Research. Dr Sosa is the recipient of grants from the Paget Foundation, the Association for Academic Surgery, the Donaghue Foundation, the American Geriatrics Association/Hartford Foundation, and the Connecticut Stem Cell Research Fund. Dr Sosa was born in Montreal and raised in upstate New York. She received her AB at Princeton University, USA, her MA at the University of Oxford, UK, and her MD at Johns Hopkins University, USA, where she also completed the Halsted residency program and a fellowship in surgical oncology while an assistant chief of service and instructor in surgery.

Back to Top | Article Outline

Pierre Hainaut

Pierre Hainaut was born and educated in Belgium. He obtained an Msc in Science in 1980 and a PhD in Biological Sciences in 1987 from the University of Liège, Belgium. From 1987 to 1994, he has held postdoctoral positions in France (INSERM) and in the UK (University of Cambridge, University of York). Most of his laboratory research was focused on molecular genetics, particularly on the tumour suppressor protein p53. He joined IARC as staff scientist in 1995 where he became head of Molecular Carcinogenesis in 1999. He is an internationally recognized scientist in the p53 mutation field and has led the development of the IARC TP53 database. His research has a focus on the molecular pathogenesis of cancers in low- and middle-resource countries, namely on tumours of the upper-aerodigestive tract (squamous cell carcinoma of the oesophagus in Iran, Kenya, Latin America; lung cancers) and on HepatoCellular Carcinoma (West Africa, Colombia, Egypt, Thailand, China). From 2002 to 2008, he has led the Gambia Hepatitis Intervention Study (GHIS), a large intervention trial aimed at testing the long-term efficacy of newborn HB vaccine against liver cancer in adults in West Africa. Since 2005 he has contributed to developing evidence-based standards for biobanks. Pierre Hainaut is frequently lecturing and giving courses in Post-Graduate programs in different countries and in international summer schools. He has written about 375 articles and book chapters and is the editor of several books on molecular epidemiology and on p53. Pierre Hainaut is a Research Director at the International Prevention Research Institute.

Back to Top | Article Outline

Amelie Plymoth

Dr Amelie Plymoth, PhD (Karolinska Institutet, Sweden) is a Swedish scientist who has worked in the field of molecular epidemiology and public health in both high and low resource countries, in academia, the pharmaceutical industry, as well as the World Health Organization (WHO).

She received her PhD in Experimental Respiratory Medicine at Lund University, Sweden in 2006. Her PhD thesis involved proteomic biomarker discovery in a large population-based prospective study on the respiratory disease Chronic Obstructive Pulmonary Disease (COPD). It was a joint collaboration between Lund University Hospital and the pharmaceutical company AstraZeneca R&D in Sweden.

Dr Plymoth has a great interest in epidemiology and global health and worked for three years as a Postdoctoral Research Fellow for the International Agency for Research on Cancer (IARC) in Lyon, France which is part of WHO. At IARC she was instrumental in the initialization and coordination of the International Liver Cancer Study (ILCS) and worked on The Gambian Hepatitis Study (GHIS).

At the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet, Dr Plymoth has been part of designing, initiating and is currently coordinating an etiologic study where the association between work-related exposures and infectious disease incidence is investigated (SWEDE-I – Studies of Work Environment and Disease Epidemiology-Infections). Her vision, for which the SWEDE-I study should be seen as a first pioneering effort, is to lay the foundation for a new avenue of research in epidemiology with the aim of reducing short-term absenteeism due to infections, and to increase the preparedness in the event of serious infectious threats and pandemics.

The group in which Dr Plymoth works has together with collaborators been leading the development and refining of population-based disease surveillance. This methodology, used in the SWEDE-I study, is a novel concept that proceeds from a representative sample of the target population, selected via random sampling from the continuously updated Swedish population register. Utilizing innovative high-tech for patient participation, data on tentative work-related risk factors, important covariates, and disease occurrence is collected. The surveillance system is unequalled in the world, and by virtue of its prospective population-based structure, it is uniquely well suited for etiological research.

During Dr Plymoth's post doctoral, PhD and master studies, she has established international collaborations and networks and worked in several research institutes around the world (Lund University, Karolinska Institutet, University of California San Francisco, USA, Fred Hutchinson Cancer Research Center, Northeastern University in Boston, USA, The Scripps Research Institute in La Jolla, USA, the International Agency for Research on Cancer in Lyon, France the Medical Research Council in The Gambia and AstraZeneca R&D in Lund, Sweden). Dr Plymoth has published several scientific articles, WHO technical reports, book chapters and standard operating procedures as well as serving as guest editor for Cancer Letters. Amelie Plymoth would like to acknowledge Gunilla Sonnebring as the photographer.

© 2013 Lippincott Williams & Wilkins, Inc.